In the above timelines, there are 2 noted—and quite obvious—patterns. The first is the extension of these biologics for use in younger populations. The second is this notable shift in the pediatric dermatology landscape that has occurred within the past year.

Up until these recent FDA approvals, pediatric dermatologists had few options and strategies to employ in their clinical practice.

Read the full article at